| 1 |
NCT01828684 |
Completed |
Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine |
- Migraine Disorders
- Photophobia
|
- Other: Therapeutic Lens Coating
- Other: Sham Lens Coating
|
Interventional
|
Not Applicable |
- Bradley Katz
- University of Utah
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HIT-6
- Headache frequency and severity
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT01828684 |
IRB_00047263 |
|
March 2013 |
January 2014 |
February 2014 |
April 11, 2013 |
March 31, 2016 |
|
- John A Moran Eye Center; University of Utah Hospitals and Clinics
Salt Lake City, Utah, United States
|
|
| 2 |
NCT01942486 |
Recruiting |
Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine |
- Migraine Disorders
- Photophobia
|
- Device: Investigational Coating
|
Interventional
|
Not Applicable |
- University of Utah
- Primary Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HIT-6 Score
- Headache Frequency as Measured Using a Self-Reporting Daily Diary
|
50 |
All |
7 Years to 18 Years (Child, Adult) |
NCT01942486 |
IRB_00065178 |
|
January 2014 |
October 2017 |
October 2017 |
September 16, 2013 |
May 3, 2017 |
|
- Moran Eye Center
Salt Lake City, Utah, United States
|
|
| 3 |
NCT00433732 |
Completed |
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches |
|
- Drug: sumatriptan
- Drug: naproxen sodium
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Trexima will be evaluated for efficacy as an acute treatment for migraine based on its superiority over placebo at 2 hours for: a) pain relief (no or mild pain), b) incidence of photophobia, c) incidence of phonophobia and d) incidence of nausea.
- a) sustained pain relief over 24 hours, b) sustained photophobia-free over 24 hours, c) sustained phonophobia-free over 24 hours, and d) sustained nausea-free over 24 hours.
|
1400 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00433732 |
MT400-302 |
|
August 2004 |
|
April 2005 |
February 12, 2007 |
February 12, 2007 |
|
- Little Rock Family Practice Clinic
Little Rock, Arkansas, United States - Pozen, Inc.
Chapel Hill, North Carolina, United States
|
|
| 4 |
NCT00330850 |
Completed |
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack |
- Migraine
- Photophobia
- Phonophobia
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Masking: Double
- Primary Purpose: Treatment
|
|
650 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00330850 |
PRO-513301 |
|
May 2006 |
|
December 2006 |
May 29, 2006 |
April 2, 2007 |
|
- Associated Neurologists of Southern CT
Fairfield, Connecticut, United States - New England Center for Headache
Stamford, Connecticut, United States - LCFP Inc.
Ft. Myers, Florida, United States - (and 13 more...)
|
|
| 5 |
NCT00825500 |
Completed
Has Results |
Staccato Loxapine in Migraine (Out Patient) |
|
- Drug: Inhaled Placebo
- Drug: Inhaled Loxapine 1.25 mg
- Drug: Inhaled Loxapine 2.5 mg
|
Interventional
|
Phase 2 |
- Alexza Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain-Relief at 2 Hours Post-treatment
- Photophobia Free
|
366 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00825500 |
AMDC-104-202
24-October-2008 |
|
January 2009 |
August 2009 |
August 2009 |
January 21, 2009 |
April 24, 2017 |
April 24, 2017 |
- Roger K. Cady
Springfield, Missouri, United States - Elkind Headache Center
Mount Vernon, New York, United States - CNS Research, Inc.
East Providence, Rhode Island, United States
|
|
| 6 |
NCT03237845 |
Completed |
Safety and Efficacy in Adult Subjects With Acute Migraines |
- Migraine Disorders
- Photophobia
- Phonophobia
- Acute Migraine
|
- Drug: Rimegepant
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain freedom of rimegepant (75 mg tablet) compared with placebo in the acute treatment of migraine will be measured using the number of evaluable subjects that report no pain at 2 hours post-dose.
- Freedom from the most bothersome symptom (MBS) of rimegepant (75 mg tablet) compared with placebo will be measured using the number of evaluable subjects that report the absence of their MBS at 2 hours post-dose.
- Rimegepant (75 mg tablet) compared to placebo from 2 to 24 hours, using the number of subjects that do not experience any headache pain through the time period of interest.
- (and 10 more...)
|
1503 |
All |
18 Years and older (Adult, Older Adult) |
NCT03237845 |
BHV3000-302 |
|
July 27, 2017 |
January 25, 2018 |
January 31, 2018 |
August 3, 2017 |
January 11, 2019 |
|
- Coastal Clinical Research
Mobile, Alabama, United States - Thunderbird Internal Medicine / Radiant Research, Inc.
Glendale, Arizona, United States - Woodland Research Northwest, LLC
Rogers, Arkansas, United States - (and 47 more...)
|
|
| 7 |
NCT03235479 |
Completed |
Safety and Efficacy Study in Adult Subjects With Acute Migraines |
- Migraine
- Acute Migraine
- Phonophobia
- Photophobia
|
- Drug: BHV-3000
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 3 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain freedom of rimegepant (75 mg tablet) compared with placebo in the acute treatment of migraine will be measured using the number of evaluable subjects that report no pain at 2 hours post-dose.
- Freedom from the most bothersome symptom (MBS) of rimegepant (75 mg tablet) compared with placebo will be measured using the number of evaluable subjects that report the absence of their MBS at 2 hours post-dose.
- To measure the difference between rimegepant (75 mg tablet) compared to placebo from 2 to 24 hours, using the number of subjects that do not experience any headache pain through the time period of interest.
- (and 10 more...)
|
1490 |
All |
18 Years and older (Adult, Older Adult) |
NCT03235479 |
BHV-3000-301 |
|
July 18, 2017 |
January 21, 2018 |
January 26, 2018 |
August 1, 2017 |
January 11, 2019 |
|
- Central Research Associates, Inc
Birmingham, Alabama, United States - Neurological Physicians of Arizona/Radiant Research Inc
Gilbert, Arizona, United States - Clinical Research Consortium Arizona
Tempe, Arizona, United States - (and 47 more...)
|
|
| 8 |
NCT03576820 |
Not yet recruiting |
Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department |
|
- Drug: Lidocaine
- Drug: Placebo
|
Interventional
|
Phase 3 |
- New York City Health and Hospitals Corporation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Pain Score
- The Number of Subjects with Improvement of Associated Symptoms
- The Number of Subjects Who Receive IV Pain Medications
- (and 3 more...)
|
50 |
All |
10 Years to 20 Years (Child, Adult) |
NCT03576820 |
2018-9278 |
|
August 2018 |
August 2019 |
December 2019 |
July 3, 2018 |
July 6, 2018 |
|
- Jacobi Medical Center
Bronx, New York, United States
|
|
| 9 |
NCT00442936 |
Completed
Has Results |
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) |
|
- Drug: Telcagepant potassium 150 mg
- Drug: Telcagepant potassium 300 mg
- Drug: Zolmitriptan 5 mg
- (and 4 more...)
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose
- Number of Participants With Pain Relief (PR) at 2 Hours Post-Dose
- Number of Participants With Absence of Photophobia at 2 Hours Post-Dose
- (and 7 more...)
|
1380 |
All |
18 Years and older (Adult, Older Adult) |
NCT00442936 |
0974-011
MK-0974-011
2006_525 |
|
February 15, 2007 |
October 2, 2007 |
October 2, 2007 |
March 5, 2007 |
October 17, 2018 |
August 4, 2014 |
|
|
| 10 |
NCT00724815 |
Completed
Has Results |
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine |
|
- Drug: NP101 - Sumatriptan iontophoretic transdermal patch
- Drug: Placebo
|
Interventional
|
Phase 3 |
- NuPathe Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain Free at Two Hours
- Photophobia Free at Two Hours
- Phonophobia Free at Two Hours
- Nausea Free at Two Hours
|
530 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00724815 |
PROT-15-NP101-007 |
NP101-007 |
January 2009 |
July 2009 |
July 2009 |
July 30, 2008 |
February 4, 2016 |
May 7, 2013 |
- Phoenix, Arizona, United States
- Little Rock, Arkansas, United States
- Newport Beach, California, United States
- (and 31 more...)
|
|
| 11 |
NCT00483704 |
Completed
Has Results |
Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) |
|
- Drug: Telcagepant 140 mg
- Drug: Talcagepant 280 mg
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack)
- Percentage of Participants Reporting Pain Relief at 2 Hours Post-dose (First Migraine Attack)
- Percentage of Participants Reporting Pain Freedom Consistency at 2 Hours Post-dose
- (and 10 more...)
|
1935 |
All |
18 Years and older (Adult, Older Adult) |
NCT00483704 |
0974-031
MK-0974-031
2007_546 |
|
August 14, 2008 |
March 25, 2009 |
March 25, 2009 |
June 7, 2007 |
October 18, 2018 |
August 29, 2014 |
|
|
| 12 |
NCT00434083 |
Completed |
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches |
|
- Drug: sumatriptan
- Drug: naproxen sodium
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Trexima will be evaluated for efficacy as an acute treatment for migraine based on its superiority over placebo at 2 hours for: a) pain relief (no or mild pain), b) incidence of photophobia, c) incidence of phonophobia and d) incidence of nausea.
- a) sustained pain relief over 24 hours, b) sustained photophobia-free over 24 hours, c) sustained phonophobia-free over 24 hours, and d) sustained nausea-free over 24 hours.
|
1200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00434083 |
MT400-301 |
|
July 2004 |
|
January 2005 |
February 12, 2007 |
February 12, 2007 |
|
- Pozen, Inc.
Chapel Hill, North Carolina, United States - Nashville Neuroscience Group, PC
Nashville, Tennessee, United States
|
|
| 13 |
NCT00792103 |
Completed
Has Results |
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months |
|
|
Interventional
|
Phase 3 |
- NuPathe Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Subject Self-examination of Skin Irritation
- Pain Relief
- Nausea Free
- (and 2 more...)
|
198 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00792103 |
PROT-15-NP101-008 |
NP101-008 |
January 2009 |
September 2010 |
September 2010 |
November 17, 2008 |
February 4, 2016 |
May 7, 2013 |
- Phoenix, Arizona, United States
- Little Rock, Arkansas, United States
- Newport Beach, California, United States
- (and 31 more...)
|
|
| 14 |
NCT03461757 |
Completed |
Trial in Adult Subjects With Acute Migraines |
|
- Drug: Rimegepant
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain freedom of rimegepant compared with placebo in the acute treatment of migraine will be measured using the number of evaluable subjects that report no pain at 2 hours post-dose.
- Freedom from the most bothersome symptom (MBS) of rimegepant compared with placebo will be measured using the number of evaluable subjects that report the absence of their MBS at 2 hours post-dose.
- To measure rimegepant compared to placebo on Pain Relief, at 2 hours post-dose, that report a pain level of moderate or severe at baseline and then report a pain level of none or mild.
- (and 17 more...)
|
1812 |
All |
18 Years and older (Adult, Older Adult) |
NCT03461757 |
BHV3000-303 |
|
February 27, 2018 |
October 8, 2018 |
October 15, 2018 |
March 12, 2018 |
November 1, 2018 |
|
- Coastal Clinical Research, LLC
Mobile, Alabama, United States - Clinical Research Consortium, An AMR Company
Tempe, Arizona, United States - Radiant Research, Inc.
Tucson, Arizona, United States - (and 66 more...)
|
|
| 15 |
NCT01973205 |
Completed
Has Results |
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine |
|
- Drug: Acetaminophen 250 mg and Aspirin 250 mg
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Subjects Who Are Pain Free at the 2-hour Assessment
- Number of Subjects Who Are Nausea Free at the 2-hour Assessment
- Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment.
- Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.
|
900 |
All |
18 Years and older (Adult, Older Adult) |
NCT01973205 |
863-P-303 |
|
October 2013 |
July 2014 |
July 2014 |
October 31, 2013 |
June 11, 2015 |
June 11, 2015 |
- Birmingham, Alabama, United States
- Anaheim, California, United States
- San Francisco, California, United States
- (and 16 more...)
|
|
| 16 |
NCT03694626 |
Not yet recruiting |
Objectively Diagnose and Monitor Treatment of Light Sensitivity |
- Photophobia
- Traumatic Brain Injury
- Migraine
|
- Device: Pupillography
- Device: Ocular Coherence Tomography (OCT)
- Device: Wrist-watch sensor device
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Randy Kardon
- University of Iowa
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Correlation of facial responses to light sensitivity
- Difference in objective biological markers of light sensitivity between light sensitive and normal subjects
- Correlation of objective biological marker of light sensitivity to optic nerve structures
- Correlation of objective biological marker of light sensitivity to macula (structure found in the back of the eye).
|
120 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03694626 |
201604763 |
|
October 15, 2018 |
July 1, 2020 |
January 1, 2021 |
October 3, 2018 |
October 3, 2018 |
|
|
|
| 17 |
NCT03361423 |
Completed |
Evaluation of a Novel Device for Treatment of Migraine Headache |
- Migraine Without Aura
- Migraine With Aura
|
- Device: Nerivio Migra-1 active device
- Device: Nerivio Migra-1 Sham device
|
Interventional
|
Not Applicable |
- Theranica
- Rambam Health Care Campus
- Northwell Health
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of reduction of migraine headache post 2 hours from treatment
- Percentage of reduction of most bothersome migraine-associated symptom (MBS) relief post 2 hours treatment
- Percentage of reduced Migraine Headache AND MBS Relief post 2 hours post tresatment
- Percentage of pain disappearance 2 hours post treatment
|
296 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03361423 |
TCH003 |
|
December 17, 2017 |
November 25, 2018 |
December 25, 2018 |
December 4, 2017 |
February 15, 2019 |
|
- Hartford Headache Center
Hartford, Connecticut, United States - Mercy Hospital
Saint Louis, Missouri, United States - Clinvest Research
Springfield, Missouri, United States - (and 9 more...)
|
|
| 18 |
NCT00449540 |
Completed
Has Results |
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura |
|
- Device: Active Transcranial Magnetic Stimulation (TMS) Device
- Device: Sham TMS Device
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percentage of Participants Experiencing no Pain at Two Hours Post-treatment
- Percentage of Participants Who Have Symptoms of Nausea
- Percentage of Participants Who Have Symptoms Phonophobia
- Percentage of Participants Who Have Photophobia
|
201 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00449540 |
NL-2006-001 |
|
August 2006 |
January 2008 |
March 2008 |
March 20, 2007 |
August 15, 2011 |
August 10, 2011 |
- San Francisco Headache Clinic
San Francisco, California, United States - Mile High Research Center
Denver, Colorado, United States - Diamond Headache Clinic, LTD
Chicago, Illinois, United States - (and 11 more...)
|
|
| 19 |
NCT02720211 |
Terminated |
Spectacle Tints and Thin-Films for Migraine |
- Headache Migraine Chronic
|
- Device: Gray tinted spectacle lenses
- Device: Thin-Film spectacle lenses
|
Interventional
|
Not Applicable |
- University of Utah
- Axon Optics, LLC
- Mayo Clinic
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Headache frequency
- Headache Impact
|
140 |
All |
18 Years to 60 Years (Adult) |
NCT02720211 |
IRB #86498 |
|
August 2016 |
November 6, 2018 |
November 6, 2018 |
March 25, 2016 |
November 8, 2018 |
|
- Mayo Clinic
Phoenix, Arizona, United States - Brigham and Women's Hospital; John R Graham Headache Center; Harvard University,
Boston, Massachusetts, United States - Headache Center of the Neuroscience Institute; Hofstra Northwell Health; Northshore University Hospital
Great Neck, New York, United States - John A Moran Eye Center; University of Utah Hospitals and Clinics
Salt Lake City, Utah, United States
|
|
| 20 |
NCT01534806 |
Withdrawn |
Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department |
|
- Drug: Ketorolac
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Akron Children's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction in the patient's pain score at 60 minutes from administration of the study medications
- number of patients achieving complete resolution of the headache while in the emergency department.
- number of patients requiring additional treatment interventions by the treating physician
- (and 3 more...)
|
0 |
All |
8 Years to 18 Years (Child, Adult) |
NCT01534806 |
110808 |
|
January 2012 |
January 2012 |
|
February 17, 2012 |
June 24, 2014 |
|
- Akron Children's Hospital
Akron, Ohio, United States
|
|
| 21 |
NCT02745392 |
Completed
Has Results |
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine |
|
- Drug: ZP-Zolmitriptan
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Zosano Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of Subjects With Pain Freedom
- Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)
|
365 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02745392 |
CP-2016-001 |
Zotrip |
June 2016 |
January 2017 |
January 2017 |
April 20, 2016 |
March 13, 2018 |
February 14, 2018 |
- Clinical Research Advantage, Inc./Thunderbird Internal Medicine
Glendale, Arizona, United States - The Research Center of Southern California
Carlsbad, California, United States - Allergy and Asthma Specialists Medical Group and Research Center
Huntington Beach, California, United States - (and 33 more...)
|
|
| 22 |
NCT00920686 |
Completed
Has Results |
Study of NXN 188 for the Treatment of Migraine With Aura |
|
- Drug: NXN-188
- Drug: placebo
- Drug: sumatriptan succinate
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time (Hours) to First Use of Rescue Medication
- Headache Relief and Recurrence (Observed Cases)
- 2 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea
- (and 2 more...)
|
239 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00920686 |
NXN-188-203 |
|
June 2009 |
March 2010 |
March 2010 |
June 15, 2009 |
August 11, 2014 |
August 11, 2014 |
- C. Philip O'Carrroll, MD, Inc.
Newport Beach, California, United States - The Research Center of Southern California, LLC
Oceanside, California, United States - San Francisco Headache Clinic
San Francisco, California, United States - (and 13 more...)
|
|
| 23 |
NCT02867709 |
Completed
Has Results |
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine |
- Migraine, With or Without Aura
|
- Drug: Ubrogepant
- Drug: Placebo-matching Ubrogepant
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose
- Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose
- Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose
- (and 5 more...)
|
1686 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02867709 |
UBR-MD-02 |
ACHIEVE II |
August 26, 2016 |
January 25, 2018 |
February 26, 2018 |
August 16, 2016 |
January 29, 2019 |
January 29, 2019 |
- Clinical Research Advantage, Inc./Simon Williamson Clinic
Birmingham, Alabama, United States - Clinical Research Advantage, Inc./East Valley Family Physicians, PLC
Chandler, Arizona, United States - St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI)
Phoenix, Arizona, United States - (and 106 more...)
|
|
| 24 |
NCT02828020 |
Completed
Has Results |
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine |
- Migraine, With or Without Aura
|
- Drug: Ubrogepant
- Drug: Placebo-matching Ubrogepant
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose
- Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose
- Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose
- (and 5 more...)
|
1672 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02828020 |
UBR-MD-01 |
ACHIEVE I |
July 22, 2016 |
December 13, 2017 |
December 14, 2017 |
July 11, 2016 |
January 3, 2019 |
January 3, 2019 |
- Clinical Research Advantage, Inc./Desert Clinical Research, LLC.
Mesa, Arizona, United States - Xenoscience, Inc.
Phoenix, Arizona, United States - Clinical Research Advantage, Inc./Orange Grove Family Practice
Tucson, Arizona, United States - (and 87 more...)
|
|
| 25 |
NCT01016678 |
Completed
Has Results |
Treximet Early Intervention Adolescent Migraine |
|
- Drug: Treximet
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Premiere Research Institute
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With 2-hour Pain Free Active Study Drug
- Percentage of Migraine Attacks With Sustained Pain Free Response From 2 to 24 Hours Post-Dose
- Percentage of Migraine Attacks With Pain Free Response at 2 Hours Post-Dose Following Early Intervention
- To Evaluate the Consistency of Response Across Four Migraine Attacks at 1, 2, 4, and 24 Hours After Treatment. Frequency of Rescue Medications Needed and the Consistency of Other Symptom Relief i.e. Nausea, Vomiting, Photophobia, and Phonophobia.
|
104 |
All |
12 Years to 17 Years (Child) |
NCT01016678 |
TEAM2009 |
TEAM |
March 2010 |
June 2014 |
July 2014 |
November 19, 2009 |
May 4, 2016 |
May 4, 2016 |
- Premiere Research Institute
West Palm Beach, Florida, United States - Andrew Hershey
Cincinnati, Ohio, United States - Steve L. Linder
Dallas, Texas, United States - Don W. Lewis
Norfolk, Virginia, United States
|
|
| 26 |
NCT00837044 |
Unknown † |
Treximet in Acute Migraine Headache: Assessing Cognitive Function |
- Migraine Headache
- Cognitive Impairment
|
- Drug: Treximet
- Drug: Migraine rescue medication of choice
|
Interventional
|
Not Applicable |
- Neurological Research Center
- GlaxoSmithKline
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
|
- To evaluate the effectiveness of treatment with Treximet versus placebo in patients with acute migraine headache on the neuropsychological function before treatment and at one and two hours after treatment of a migraine.
- To assess incidence and types of neuropsychological deficits by MEWT in patients with acute migraine headache before treatment.
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00837044 |
112488 |
|
February 2009 |
July 2009 |
September 2009 |
February 5, 2009 |
February 5, 2009 |
|
- The Neurological Research center, Inc
Bennington, Vermont, United States
|
|
| 27 |
NCT03026101 |
Recruiting |
Understanding the Pathophysiology of Migraine Pain |
- Migraine Disorders
- Migraine, Classic
- Migraine Without Aura
|
|
Interventional
|
Not Applicable |
- Montefiore Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Migraine
- Migraine log pre-procedure: severity measure
- Migraine log pre-procedure: frequency measure
- (and 17 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03026101 |
2017-8335 |
|
January 2017 |
January 2019 |
June 2019 |
January 20, 2017 |
April 24, 2018 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 28 |
NCT02748577 |
Recruiting |
Pain Processing in Adults With Migraines |
|
- Other: Questionnaires
- Other: Quantitative Sensory Testing (QST) Pain Measurements
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Heat Pain Intensity coefficient and intercept from stimulus response curve
- Heat Pain Unpleasantness coefficient and intercept from stimulus response curve
- Pain Catastophizing score
- (and 13 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02748577 |
IRB00027845 |
|
January 2016 |
July 2020 |
July 2020 |
April 22, 2016 |
November 14, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 29 |
NCT00210496 |
Completed |
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine |
- Migraine
- Classic Migraine
- Common Migraine
|
- Drug: topiramate; almotriptan malate
|
Interventional
|
Phase 4 |
- Janssen-Ortho LLC
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary effectiveness parameter will be the proportion of subjects in each treatment group who achieve a Sustained Pain Free (SPF) response during the first qualifying headache of the Assessment Period.
- For first headache of the Assessment Period, Pain relief at 2 hours; Pain free at 2 hours; Maximum intensity of headache pain; Headache duration; Rescue medication use; Maximum intensity of migraine associated symptoms (photophobia, phonophobia, nausea).
|
406 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00210496 |
CR002875 |
|
June 2005 |
|
June 2007 |
September 21, 2005 |
May 17, 2011 |
|
|
|
| 30 |
NCT00293657 |
Completed |
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine. |
|
- Drug: Lornoxicam 8 mg
- Drug: Lornoxicam 16 mg
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Assessment of headache pain intensity over 24 hours after treatment, rated on a categorical scale of 0-3 and a visual analog scale (VAS).
- Assessments of symptoms of photophobia, phonophobia, nausea and vomiting, rated as present or absent; use of rescue medication in the 24 hours after dosing; response of allodynia symptoms present at time of treatment.
|
150 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00293657 |
LNP-201 |
|
December 2005 |
April 2006 |
April 2006 |
February 17, 2006 |
December 3, 2012 |
|
- Alabama Clinical Therapeutics
Birmingham, Alabama, United States - University of South Alabama Neurology
Mobile, Alabama, United States - Little Rock Family Practice Clinic
Little Rock, Arkansas, United States - (and 20 more...)
|
|
| 31 |
NCT01513291 |
Completed
Has Results |
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020) |
|
- Drug: MK-6096
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mean Change From Baseline in Monthly Migraine Days
- Percentage of Participants With One or More Adverse Events
- Percentage of Participants Discontinued From Study Medication Due to an Adverse Event
- (and 3 more...)
|
237 |
All |
18 Years to 64 Years (Adult) |
NCT01513291 |
6096-020 |
|
February 6, 2012 |
October 3, 2012 |
October 3, 2012 |
January 20, 2012 |
November 7, 2018 |
July 20, 2016 |
|
|
| 32 |
NCT02163993 |
Completed
Has Results |
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase
- Mean Change From Baseline in Number of Migraine Attacks in the Last 28-Day Period of the 12-Week Treatment Phase
- Percentage of Participants With ≥50% Reduction in Number of Migraine Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase
- (and 10 more...)
|
414 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02163993 |
15414
I5Q-MC-CGAB |
|
July 7, 2014 |
August 19, 2015 |
February 12, 2018 |
June 16, 2014 |
November 22, 2018 |
November 22, 2018 |
- Clinical Research Advantage
Gilbert, Arizona, United States - 21st Century Neurology
Phoenix, Arizona, United States - Arizona Research Center
Phoenix, Arizona, United States - (and 37 more...)
|
|
| 33 |
NCT00623636 |
Completed
Has Results |
Phase 3 Study of MAP0004 in Adult Migraineurs |
|
- Drug: MAP0004
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Allergan
- MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Subjects With Pain Relief at 2 Hours From Time of First Dose
- Number of Subjects Photophobia Free at 2 Hours From Time of First Dose
- Number of Subjects Phonophobia Free at 2 Hours From Time of First Dose
- (and 5 more...)
|
902 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00623636 |
MAP0004 CL P301 |
FREEDOM301 |
July 2008 |
December 2010 |
January 2011 |
February 26, 2008 |
January 9, 2014 |
October 29, 2013 |
- Swedish Pain and Headache Clinic
Seattle, Washington, United States
|
|
| 34 |
NCT02605174 |
Completed
Has Results |
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine |
- Migraine With or Without Aura
|
- Drug: Lasmiditan 50 mg
- Drug: Lasmiditan 100 mg
- Drug: Lasmiditan 200 mg
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Eli Lilly and Company
- CoLucid Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants Headache Pain Free at 2 Hours Post Dose
- Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free
|
3005 |
All |
18 Years and older (Adult, Older Adult) |
NCT02605174 |
16889
H8H-CD-LAHK
2015-005689-40
COL MIG-302 |
SPARTAN |
May 2016 |
June 30, 2017 |
June 30, 2017 |
November 16, 2015 |
July 30, 2018 |
July 30, 2018 |
- Alabama Clinical Therapeutics, LLC
Birmingham, Alabama, United States - Medical Affiliated Research Center, Inc. - ARC
Huntsville, Alabama, United States - 21st Century Neurology
Phoenix, Arizona, United States - (and 92 more...)
|
|
| 35 |
NCT03152305 |
Recruiting |
Intracranial Pressure During Migraine |
|
- Other: Intracranial pressure variations
|
Observational
|
|
- University Hospital, Clermont-Ferrand
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Intracranial pressure variations
- Relationships between ICP variations and clinical parameters
- Relationships between ICP variations and pain relief
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT03152305 |
CHU-331
2014-A00042-45 |
MigICP |
July 21, 2014 |
May 2017 |
July 2018 |
May 15, 2017 |
May 15, 2017 |
|
- CHU Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
|
|
| 36 |
NCT03806595 |
Not yet recruiting |
Intranasal Lidocaine in Acute Management of Pediatric Migraine and Migraine-like Headache |
- Migraine in Children
- Posttraumatic Headache
|
- Drug: Lidocaine 2% Injectable Solution
- Drug: Normal Saline Flush, 0.9% Injectable Solution
|
Interventional
|
Phase 4 |
- University of British Columbia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in migraine pain
- Rebound headache
- Emergency department length of stay
- (and 2 more...)
|
132 |
All |
7 Years to 16 Years (Child) |
NCT03806595 |
H18-03801 |
|
February 1, 2019 |
August 31, 2020 |
September 4, 2020 |
January 16, 2019 |
January 16, 2019 |
|
- BC Children's Hospital
Vancouver, British Columbia, Canada
|
|
| 37 |
NCT01687088 |
Completed
Has Results |
Smell Sensitivity in Chronic Migraine: A Case-Control Study |
- Chronic Migraine
- Olfactory Acuity
|
|
Observational
|
|
- Thomas Jefferson University
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Comparison of UPSIT Scores Between Subjects and Controls at Two Time Points
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT01687088 |
MJM/Olfactory/002 |
|
July 2011 |
March 2012 |
March 2012 |
September 18, 2012 |
October 24, 2014 |
October 24, 2014 |
|
|
| 38 |
NCT00203346 |
Completed |
Research Study Examining Nerve Block for Migraine |
|
- Procedure: Greater Occipital Nerve Block
|
Observational
|
|
- Thomas Jefferson University
|
Other |
- Time Perspective: Prospective
|
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00203346 |
WBY/GON |
|
June 2005 |
|
|
September 20, 2005 |
January 23, 2009 |
|
- Jefferson Headache Center
Philadelphia, Pennsylvania, United States
|
|
| 39 |
NCT02614183 |
Completed
Has Results |
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days
- Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days
- Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 (v2.1) Role Function Restrictive Domain
- (and 7 more...)
|
862 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02614183 |
15767
I5Q-MC-CGAG |
EVOLVE-1 |
November 30, 2015 |
March 22, 2017 |
August 9, 2018 |
November 25, 2015 |
November 29, 2018 |
November 29, 2018 |
- Territory Neurology & Research Institute
Tucson, Arizona, United States - Orange Grove Family Practice
Tucson, Arizona, United States - Arkansas Clinical Research
Little Rock, Arkansas, United States - (and 92 more...)
|
|
| 40 |
NCT01248468 |
Completed
Has Results |
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine |
|
- Drug: Aspirin, acetaminophen and caffeine
- Drug: Sumatriptan
- Drug: Placebo
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percent of Subjects Who Are Pain Free at 2 Hours.
- Percent of Subjects Who Are Free of Nausea at 2 Hours.
- Percent of Subjects Who Are Free of Phonophobia at 2 Hours.
- Percent of Subjects Who Are Free of Photophobia at 2 Hours.
|
752 |
All |
18 Years and older (Adult, Older Adult) |
NCT01248468 |
176-P-401 |
|
November 2010 |
March 2011 |
March 2011 |
November 25, 2010 |
July 30, 2012 |
July 30, 2012 |
- Anaheim, California, United States
- San Francisco, California, United States
- Clearwater, Florida, United States
- (and 17 more...)
|
|
| 41 |
NCT02614196 |
Completed
Has Results |
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days
- Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days
- Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain
- (and 7 more...)
|
986 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02614196 |
15768
I5Q-MC-CGAH
2015‐001882‐17 |
EVOLVE-2 |
December 4, 2015 |
March 29, 2017 |
October 5, 2018 |
November 25, 2015 |
January 7, 2019 |
January 7, 2019 |
- 21st Century Neurology
Phoenix, Arizona, United States - Arizona Research Center
Phoenix, Arizona, United States - Axiom Research
Apple Valley, California, United States - (and 110 more...)
|
|
| 42 |
NCT00432237 |
Completed
Has Results |
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) |
|
- Drug: MK0974 50 mg
- Drug: MK0974 150 mg
- Drug: MK0974 300 mg
- Drug: Comparator: Placebo
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Patients Reporting Pain Freedom at 2 Hours Postdose
- Number of Patients Reporting Pain Relief at 2 Hours Post Dose
- Number of Patients Reporting Absence of Photophobia at 2 Hours Post Dose
- (and 5 more...)
|
1703 |
All |
18 Years and older (Adult, Older Adult) |
NCT00432237 |
0974-016
2006_526 |
|
March 2007 |
December 2007 |
December 2007 |
February 7, 2007 |
July 3, 2015 |
December 6, 2010 |
|
|
| 43 |
NCT03009019 |
Active, not recruiting |
Efficacy, Tolerability, and Safety of DFN-15 |
|
- Drug: DFN-15 Active
- Other: DFN-15 Placebo
|
Interventional
|
Phase 3 |
- Dr. Reddy's Laboratories Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of subjects who are pain-free at 2 hours postdose (first treated double-blind treatment period)
- Proportion of subjects who are free from their most bothersome symptom among nausea, photophobia, and phonophobia at 2 hours postdose (first double-blind treatment period)
|
631 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03009019 |
DFN-15-CD-006 |
|
December 2016 |
November 2017 |
April 2019 |
January 4, 2017 |
February 6, 2019 |
|
- Site 609
Birmingham, Alabama, United States - Site 640
Mobile, Alabama, United States - Site 622
Tucson, Arizona, United States - (and 40 more...)
|
|
| 44 |
NCT03006276 |
Active, not recruiting |
Efficacy, Tolerability, and Safety Study of DFN-15 |
|
- Drug: DFN-15 Active
- Other: DFN-15 Placebo
|
Interventional
|
Phase 3 |
- Dr. Reddy's Laboratories Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of subjects who are pain-free at 2 hours postdose (first double-blind treatment period)
- Proportion of subjects who are free from their most bothersome symptom among nausea, photophobia, and phonophobia at 2 hours postdose (first double-blind treatment period.
|
622 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03006276 |
DFN-15-CD-007 |
|
December 2016 |
November 2017 |
April 2019 |
December 30, 2016 |
February 6, 2019 |
|
- Site 744
Birmingham, Alabama, United States - Site 727
Phoenix, Arizona, United States - Site 723
Little Rock, Arkansas, United States - (and 42 more...)
|
|
| 45 |
NCT03732638 |
Recruiting |
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults |
|
- Drug: Rimegepant
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in mean number of migraine days per month
- Achievement of at least a 50% reduction from baseline in mean monthly migraine days.
- The mean number of rescue medication days per month.
- (and 4 more...)
|
1200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03732638 |
BHV3000-305 |
|
November 14, 2018 |
September 30, 2019 |
February 15, 2020 |
November 6, 2018 |
January 9, 2019 |
|
- MedPharmics, LLC
Phoenix, Arizona, United States - Tucson Neuroscience Research
Tucson, Arizona, United States - Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - (and 72 more...)
|
|
| 46 |
NCT02630719 |
Completed |
Timolol Eye Drops in the Treatment of Acute Migraine Headache |
|
- Drug: Timolol eye drops
- Drug: Artificial tears
|
Interventional
|
Not Applicable |
- University of Missouri, Kansas City
- Truman Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Timolol Eye Drops in the Treatment of Acute Migraine Headache
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02630719 |
15-152
#15-060 |
|
January 2016 |
August 1, 2017 |
August 1, 2017 |
December 15, 2015 |
April 24, 2018 |
|
- Truman Medical Center
Kansas City, Missouri, United States
|
|
| 47 |
NCT00257010 |
Completed
Has Results |
A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches |
|
|
Interventional
|
Phase 3 |
- Janssen-Ortho LLC
- Ortho-McNeil Neurologics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Pain Free Headaches at 2 and 24 Hours Post-Dose
- Number of Headaches Achieving Pain Relief at 2 and 24 Hours Post-Dose
- Number of Headaches With Photophobia
- (and 3 more...)
|
447 |
All |
12 Years to 17 Years (Child) |
NCT00257010 |
CR002827
CAPSS-368 |
|
December 2005 |
December 2007 |
December 2007 |
November 22, 2005 |
February 21, 2014 |
December 6, 2013 |
- Mobile, Alabama, United States
- Montgomery, Alabama, United States
- Oxford, Alabama, United States
- (and 46 more...)
|
|
| 48 |
NCT00712725 |
Completed
Has Results |
MK3207 for Treatment of Acute Migraines (3207-005) |
|
- Drug: MK3207- 2.5 mg
- Drug: MK3207- 5 mg
- Drug: MK3207- 10 mg
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain Freedom (PF)
- Pain Relief (PR)
- Absence of Photophobia
- (and 3 more...)
|
676 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00712725 |
3207-005
2008_536 |
|
July 2008 |
January 2009 |
January 2009 |
July 10, 2008 |
February 2, 2015 |
November 22, 2010 |
|
|
| 49 |
NCT00797667 |
Terminated
Has Results |
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) |
|
- Drug: Telcagepant 140 mg
- Drug: Telcagepant 280 mg
- Drug: 140 mg telcagepant placebo
- Drug: 280 mg telcagepant placebo
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Mean Monthly Headache Days
- Change From Baseline in Mean Monthly Migraine Days
- Percentage of Participants Who Experienced an Adverse Event
- (and 4 more...)
|
660 |
All |
18 Years and older (Adult, Older Adult) |
NCT00797667 |
0974-049
2008_591 |
|
November 12, 2008 |
May 20, 2009 |
May 20, 2009 |
November 25, 2008 |
October 18, 2018 |
September 8, 2014 |
|
|
| 50 |
NCT00329732 |
Terminated
Has Results |
Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks |
|
- Drug: 0.5% bupivicaine and 2% lidocaine
- Drug: Saline placebo
|
Interventional
|
Not Applicable |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Patients Experiencing Significant Change on a 4 Point Pain Scale at 30 Minutes Post-injection, Active Drug Versus Placebo. Significant Change is Defined as a Change on the 4 Point Pain Scale From Moderate or Severe to Mild. No Pain Equals 0.
- Secondary Measures Include:Percentage of Subjects Achieving a Significant Change on a 10 Point Pain Scale at 30 Minutes Post-injection, Active Drug Versus Placebo;
- Percentage of Subjects Achieving a Significant Change on a 100mm Visual Analogue Scale (VAS) at 30 Minutes Post-injection, Active Drug Versus Placebo. Significant Change is Defined as a Greater Than or Equal to 2cm Change.
- Percentage of Subjects Achieving Resolution of Associated Symptoms of Nausea, Vomiting, Photophobia, Phonophobia, Osmophobia, Allodynia Measured During the First 30 Minutes Post-injection, Active Drug Versus Placebo;
|
2 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00329732 |
GON-DBPC/WBY |
|
March 2006 |
April 2006 |
April 2006 |
May 25, 2006 |
May 6, 2015 |
June 27, 2011 |
- Jefferson Headache Center/Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 51 |
NCT01532830 |
Completed
Has Results |
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine |
|
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety - Number of Participants With Adverse Effects
- Mean Change in Headache Pain From Baseline to 120 Minutes
- Change in Photophobia (Visual) From Baseline to 120 Minutes
- (and 3 more...)
|
30 |
All |
18 Years to 55 Years (Adult) |
NCT01532830 |
M-US-01 |
|
February 2012 |
July 2012 |
July 25, 2012 |
February 15, 2012 |
July 10, 2018 |
May 11, 2018 |
- UCSF Headache Center
San Francisco, California, United States - Montefiore Headache Center
Bronx, New York, United States - New York Headache Center
New York, New York, United States
|
|
| 52 |
NCT03598075 |
Recruiting |
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients |
|
- Other: Amylin (Pramlintide)
- Other: CGRP
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Headache intensity
- Headache characteristics
- Dilatation of Arteria radialis and arteria temporalis superficialis
- (and 2 more...)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT03598075 |
H-17035931 |
|
July 1, 2018 |
July 1, 2019 |
July 1, 2019 |
July 25, 2018 |
August 7, 2018 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 53 |
NCT01253915 |
Terminated |
The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine |
|
- Drug: Nasal Carbon Dioxide
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Capnia, Inc.
- Walter Reed National Military Medical Center
- United States Naval Medical Center, San Diego
- (and 2 more...)
|
Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The proportion of patients who are pain-free
- The proportion of patients who are nausea/vomiting free
- The proportion of patients who are phonophobia free
- The proportion of patients who are photophobia free
|
35 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01253915 |
C113 |
|
January 2012 |
April 2013 |
June 2013 |
December 6, 2010 |
October 31, 2013 |
|
- Naval Medical Center San Diego - Dept of Neurology
San Diego, California, United States - Walter Reed National Military Medical Center - Dept of Neurology
Bethesda, Maryland, United States - Naval Medical Center Portsmouth - Dept of Neurology
Portsmouth, Virginia, United States
|
|
| 54 |
NCT00727974 |
Recruiting |
Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines |
|
|
Observational
|
|
- Medical College of Wisconsin
- Children's Hospital and Health System Foundation, Wisconsin
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Identify novel genes that contribute to the risk of CVS using genomewide association analysis approach.
- Perform genotype-phenotype correlations between genetic profiles and various phenotypes of CVS (e.g. menstrual, Sato, calendar-tied) and migraine headaches (e.g. with aura, without aura, hemiplegic migraine)
|
880 |
All |
up to 21 Years (Child, Adult) |
NCT00727974 |
08/24
GC 607 |
|
January 2008 |
December 2019 |
December 2019 |
August 5, 2008 |
March 23, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 55 |
NCT00382993 |
Completed
Has Results |
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) |
|
- Drug: Placebo
- Drug: Combination Product (sumatriptan succinate/naproxen sodium)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose
- Migraine Headache Pain Free at 2 Hours Post-Dose
- Rescue Medication Use During 0 - 24 Hours Post-Dose
- (and 16 more...)
|
169 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00382993 |
TRX106573 |
|
December 2006 |
November 2007 |
November 2007 |
October 2, 2006 |
February 2, 2017 |
April 20, 2010 |
- GSK Investigational Site
Jasper, Alabama, United States - GSK Investigational Site
Oceanside, California, United States - GSK Investigational Site
San Francisco, California, United States - (and 25 more...)
|
|
| 56 |
NCT00383162 |
Completed
Has Results |
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) |
|
- Drug: Combination Product (sumatriptan succinate / naproxen sodium)
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose
- Pain-Free Assessment at 2 Hours Post-dose
- Rescue Medication Used up to 24 Hours Post-dose
- (and 16 more...)
|
173 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00383162 |
TRX106571 |
|
November 2006 |
October 2007 |
October 2007 |
October 2, 2006 |
February 2, 2017 |
February 17, 2010 |
- GSK Investigational Site
Fresno, California, United States - GSK Investigational Site
Newport Beach, California, United States - GSK Investigational Site
Santa Monica, California, United States - (and 23 more...)
|
|
| 57 |
NCT01657370 |
Completed
Has Results |
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) |
|
- Drug: MK-1602
- Drug: Placebo
- Drug: Rescue medication
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Dry Blood Spot (DBS) MK-1602 Concentration at 2 Hours Post-Dose on Migraine Treatment Day
- Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose on Migraine Treatment Day
- Percentage of Participants With Pain Relief (PR) at 2 Hours Post-Dose on Migraine Treatment Day
- (and 7 more...)
|
195 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01657370 |
1602-007 |
|
August 2012 |
November 2012 |
December 2012 |
August 6, 2012 |
December 9, 2016 |
December 9, 2016 |
|
|
| 58 |
NCT00843024 |
Completed
Has Results |
Migraine Study in Adolescent Patients |
|
- Drug: Sumatriptan and Naproxen Sodium
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants Who Were Pain Free at 2 Hours Post-dose
- Number of Participants Sustained Pain-free From 2-24 Hours
- Number of Participants Photophobia-free at 2 Hours Post-dose
- (and 8 more...)
|
589 |
All |
12 Years to 17 Years (Child) |
NCT00843024 |
107979 |
|
December 2008 |
May 2010 |
June 2010 |
February 13, 2009 |
January 18, 2017 |
May 9, 2011 |
- GSK Investigational Site
Gilbert, Arizona, United States - GSK Investigational Site
Litchfield Park, Arizona, United States - GSK Investigational Site
Phoenix, Arizona, United States - (and 76 more...)
|
|
| 59 |
NCT03465904 |
Completed |
A Phase III Trial of e-TNS for the Acute Treatment of Migraine |
|
- Device: Verum Cefaly® Abortive Program device
- Device: Sham Cefaly® Abortive Program device
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain Freedom at 2 hours
- Most bothersome migraine-associated symptom freedom at 2 hours
- Pain Relief at 2 hours
- (and 4 more...)
|
626 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03465904 |
51401 |
TEAM |
April 10, 2018 |
January 11, 2019 |
January 11, 2019 |
March 14, 2018 |
January 21, 2019 |
|
- Clinical Research Consortium
Tempe, Arizona, United States - Pharmacology Research Institute
Encino, California, United States - Yale University
New Haven, Connecticut, United States - (and 7 more...)
|
|
| 60 |
NCT01613248 |
Completed
Has Results |
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) |
|
- Drug: MK-1602
- Drug: Placebo-matching MK-1602
- Drug: Rescue medication
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose
- Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose
- Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose
- (and 12 more...)
|
834 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01613248 |
1602-006 |
|
July 1, 2012 |
December 1, 2012 |
December 1, 2012 |
June 7, 2012 |
January 8, 2019 |
September 30, 2016 |
|
|
| 61 |
NCT02706015 |
Not yet recruiting |
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks |
|
- Drug: Cefaliv® & Placebo
- Drug: Neosaldina® & Placebo
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Evaluate the efficacy and non-inferiority of Cefaliv® compared to Neosaldina® in pain relief
- The remission of the pain after use of the investigational product, without use of a rescue medication;
- The relief of pain after use of the investigational product, without use of a rescue medication;
- (and 3 more...)
|
216 |
All |
18 Years to 66 Years (Adult, Older Adult) |
NCT02706015 |
ACH-CFL-03(10/14) |
|
October 2020 |
May 2021 |
July 2021 |
March 11, 2016 |
April 9, 2018 |
|
- Ache Laboratorios Farmaceuticos
Guarulhos, São Paulo, Brazil
|
|
| 62 |
NCT00897104 |
Completed
Has Results |
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029) |
|
- Drug: rizatriptan benzoate (MK0462)
- Drug: Comparator: sumatriptan
- Drug: Comparator: Placebo
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain Relief at 2 Hours After Treatment
- Time to Relief Within 2 Hours After Treatment
- Pain Free at 2 Hours After Treatment
- (and 4 more...)
|
933 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00897104 |
0462-029
2009_593 |
|
August 1995 |
May 1996 |
September 1996 |
May 12, 2009 |
March 4, 2015 |
July 23, 2010 |
|
|
| 63 |
NCT01294046 |
Completed
Has Results |
Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches |
|
- Device: Deep Brain Stimulation of SPG for Migraine
|
Interventional
|
Not Applicable |
- The Cleveland Clinic
- Autonomic Technologies, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine Relief at 2 Hours Post Stimulation
- Migraine Free at 2 Hours
- Pain Free at 2 Hours Post Stimulation
- (and 7 more...)
|
3 |
All |
18 Years and older (Adult, Older Adult) |
NCT01294046 |
IDE Number : G100007 |
|
March 2011 |
March 2014 |
March 2014 |
February 11, 2011 |
April 14, 2017 |
March 7, 2017 |
- Cleveland Clinic
Cleveland, Ohio, United States
|
|
| 64 |
NCT00516737 |
Completed
Has Results |
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081) |
|
- Drug: Comparator: rizatriptan benzoate
- Drug: Comparator: Placebo
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants Who Are Pain Free at 2 Hours Post-Dose
- Number of Participants With 24-Hour Sustained Pain Freedom
- Number of Participants With no Rescue Use up to 24 Hours Post-Dose
- (and 4 more...)
|
207 |
All |
18 Years and older (Adult, Older Adult) |
NCT00516737 |
0462-081
2007_547 |
|
October 3, 2007 |
April 8, 2008 |
April 8, 2008 |
August 15, 2007 |
June 9, 2017 |
April 14, 2009 |
|
|
| 65 |
NCT03159000 |
Recruiting |
A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks |
|
- Drug: Saline
- Combination Product: lidocaine/bupivacaine
|
Interventional
|
Phase 4 |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of subjects experiencing headache improvement at 2 hours
- Percentage of subjects experiencing headache improvement 10 minutes
- Percentage of subjects experiencing headache improvement at 30 minutes
- (and 7 more...)
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03159000 |
GON/WBY/003 |
|
May 1, 2017 |
December 31, 2017 |
June 30, 2018 |
May 18, 2017 |
May 18, 2017 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 66 |
NCT02057315 |
Completed |
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine |
|
- Drug: ELS-M11
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of patients who experience pain relief 2 hours following the first application of ELS-M11
- Percentage of patients who report pain relief at various time points within a 24 hour period, following the first application of ELS-M11
- Percentage of patients who report complete pain resolution within 24 hours following the first application of ELS-M11.
- (and 6 more...)
|
48 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02057315 |
ACH10200 |
|
March 2014 |
November 2014 |
November 2014 |
February 7, 2014 |
July 11, 2017 |
|
- Michigan Head Pain and Neurological Institute
Ann Arbor, Michigan, United States - Coastal Carolina Research Center
Charleston, South Carolina, United States
|
|
| 67 |
NCT00662818 |
Completed
Has Results |
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) |
- Migraine Disorders
- Heart Disease
- Cerebrovascular Accident
- (and 3 more...)
|
- Drug: Telcagepant
- Drug: Acetaminophen/Paracetamol
- Drug: Placebo to Telcagepant
- Drug: Placebo to Acetaminophen/Paracetamol
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants With Pain Freedom at 2 Hours Post-dose (Period 1, Migraine Attack 1)
- Number of Participants Who Experienced an Adverse Event (AE) Within 14 Days Post-dose
- Number of Participants Discontinuing Study Drug Due to an AE Within 48 Hours Post-dose
- (and 6 more...)
|
165 |
All |
18 Years and older (Adult, Older Adult) |
NCT00662818 |
0974-034
MK-0974-034
2007_545 |
|
March 17, 2008 |
September 2, 2009 |
September 2, 2009 |
April 21, 2008 |
October 19, 2018 |
September 17, 2014 |
|
|
| 68 |
NCT01430442 |
Completed |
Dose Ranging Study of a Drug for the Treatment of Acute Migraine |
|
- Drug: Placebo matching BMS-927711
- Drug: BMS-927711
- Drug: Sumatriptan
|
Interventional
|
Phase 2 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain Freedom (from migraine pain)
- Total migraine freedom (pain freedom, coupled with no symptoms of phonophobia, photophobia, or nausea)
- Frequency and severity of adverse events
- Sustained pain freedom
|
885 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01430442 |
CN170-003 |
|
October 2011 |
May 2012 |
May 2012 |
September 8, 2011 |
February 21, 2018 |
|
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - Clinical Res. Advantage Inc/ Desert Clinical Research Llc
Tempe, Arizona, United States - University Of California, San Francisco
San Francisco, California, United States - (and 38 more...)
|
|
| 69 |
NCT00573170 |
Completed
Has Results |
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults |
- Migraine Disorders
- Migraine, Acute
|
- Drug: TREXIMET®
- Drug: Butalbital-containing Combination Medications (BCM)
- Drug: placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose
- Number of Participants With a Pain-free Response From 2 to 48 Hours Post-dose
- Number of Participants Using Rescue Medication Within 48 Hours Post Dose
- (and 20 more...)
|
375 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00573170 |
TRX109011/TRX109013 |
|
February 2008 |
August 2009 |
August 2009 |
December 14, 2007 |
December 29, 2010 |
December 29, 2010 |
- GSK Investigational Site
Chandler, Arizona, United States - GSK Investigational Site
Gilbert, Arizona, United States - GSK Investigational Site
Litchfield Park, Arizona, United States - (and 104 more...)
|
|
| 70 |
NCT02903680 |
Recruiting |
RCT of IV Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Paediatric ED |
|
- Drug: Dexamethasone group
- Drug: Placebo group
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- incidence of relapse following discharge from the ED
- mean level of pain
- associated symptoms (i.e. nausea, vomiting, photophobia and sonophobia),
- (and 2 more...)
|
116 |
All |
8 Years to 18 Years (Child, Adult) |
NCT02903680 |
3662 |
|
May 2014 |
May 2019 |
June 2019 |
September 16, 2016 |
October 20, 2017 |
|
- CHU Sainte Justine
Montréal, Quebec, Canada
|
|
| 71 |
NCT00203294 |
Completed
Has Results |
A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache |
|
- Drug: lidocaine, bupivicaine and saline
- Drug: lidocaine plus bupivicaine plus triamcinolone (steroid)
|
Interventional
|
Not Applicable |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Headache Severity as Measured on an 11-point Verbal Scale (0 to 10):0=No Pain 10=Excruciating Pain
- Decrease in Headache Pain, as Measured on an 11-point Pain Scale (0=no Pain, 10=Excruciating Pain). Change in Headache Pain 20 Minutes After Injection Will be Compared Between Treatment Groups.
- To Evaluate the Effect of Treatment on Neck Pain in the Two Groups Compared to Historical Baseline, and Between the Two Treatment Groups.
- To Evaluate Effect of Treatment on Associated Symptoms (Nausea, Phonophobia and Photophobia) as Measured Using a 4 Point Scale (None, Mild, Moderate, Severe) Compared to Historical Baseline, and Between the Two Treatment Groups.
|
45 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00203294 |
GONB/ STE/ 01 |
|
June 2005 |
June 2006 |
June 2006 |
September 20, 2005 |
May 7, 2014 |
May 7, 2014 |
- Jefferson Headache Center
Philadelphia, Pennsylvania, United States
|
|
| 72 |
NCT00963937 |
Completed
Has Results |
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents |
|
- Drug: Sumatriptan 25 mg
- Drug: Sumatriptan 50 mg
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment
- Percentage of Participants Who Reported Pain Relief at 30, 60, 120, and 240 Minutes Post-Treatment
- Percentage of Participants Who Were Pain Free at 30, 60, 120, and 240 Minutes Post-Treatment
- (and 5 more...)
|
178 |
All |
10 Years to 17 Years (Child) |
NCT00963937 |
111035 |
|
September 28, 2009 |
December 1, 2010 |
December 3, 2010 |
August 24, 2009 |
August 6, 2018 |
August 26, 2011 |
- GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Hokkaido, Japan - (and 13 more...)
|
|
| 73 |
NCT01807234 |
Completed
Has Results |
Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine |
|
- Drug: Ketorolac
- Drug: Sumatriptan
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Johns Hopkins University
- American Regent, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- 2- Hour Pain Relief
- Pain Freedom
- Absence of Photophobia
- (and 7 more...)
|
72 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01807234 |
NA00075486 |
KSPN |
February 2013 |
December 2014 |
December 2014 |
March 8, 2013 |
March 13, 2017 |
March 13, 2017 |
- The Johns Hopkins Bayview Headache Center
Baltimore, Maryland, United States
|
|
| 74 |
NCT00893737 |
Completed
Has Results |
"Completeness of Response" Following Treatment With Treximet™ for Migraine |
|
- Drug: sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
|
Interventional
|
Phase 4 |
- Cady, Roger, M.D.
- GlaxoSmithKline
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Scores From Completeness of Response Survey (CORS)
- Percent of Participants Reporting Treximet Provides Therapeutic Advantage Over Usual Pre-study Triptan
- Paired T-test Indicating Greater Subject Satisfaction With Treximet Over Usual Pre-study Triptan as Determined by the Revised Patient Perception of Migraine Questionnaire (PPMQ-R)
|
147 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00893737 |
110211 |
|
June 2009 |
January 2010 |
January 2010 |
May 6, 2009 |
January 25, 2011 |
January 25, 2011 |
- San Francisco Clinical Research Center
San Francisco, California, United States - Westside Family Medical Center
Kalamazoo, Michigan, United States - Clinvest
Springfield, Missouri, United States - (and 5 more...)
|
|
| 75 |
NCT02686034 |
Unknown † |
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks |
|
- Device: gammaCore-S
- Device: gammaCore-S Sham
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment Response - No Pain
- Nausea/Vomiting
- Treatment Response - No Pain or Mild Pain
- Sustained Treatment Response
|
300 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02686034 |
GM-16 |
|
January 2016 |
December 2016 |
April 2017 |
February 19, 2016 |
November 28, 2016 |
|
- University Aldo Moro, Ospedale Pediatrico
Bari, Italy - IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria
Bologna, Italy - University Hospital of Careggi
Florence, Italy - (and 7 more...)
|
|
| 76 |
NCT01986088 |
Completed |
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study |
- Migraine With or Without Aura
|
- Drug: Placebo
- Drug: Eletriptan 40 mg
- Drug: Eletriptan 80 mg
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Headache response at 1 hour after treatment of the first attack.
- Headache severity
- Pain-free response
- (and 2 more...)
|
1008 |
All |
18 Years to 76 Years (Adult, Older Adult) |
NCT01986088 |
A160-318 |
|
November 1996 |
January 1998 |
January 1998 |
November 18, 2013 |
November 18, 2013 |
|
|
|
| 77 |
NCT01726920 |
Withdrawn |
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine. |
|
- Drug: naratriptan + naproxen
- Drug: naratriptan
- Drug: naproxen
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Headache relief 2 hours after dosing, without use of rescue medication
- Headache relief 4 hours after dosing, without use of rescue medication
- Maintenance of pain relief between 2 and 24 hours after dosing, without use of rescue medication
- (and 7 more...)
|
0 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01726920 |
ACH-NRP-03(04/12) |
Copérnico |
July 2014 |
December 2014 |
|
November 15, 2012 |
March 16, 2016 |
|
|
|
| 78 |
NCT03787238 |
Not yet recruiting |
A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine (REAL) |
|
- Device: non-invasive vagus nerve stimulation
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction in number of migraine days during the last four weeks in the twelve-week randomized period compared with the four-week run-in period
- Reduction in number of headache days during the last four-weeks in the twelve-week randomized period compared to the four-week run-in period
- Reduction in number of migraine days and headache days (separately)
- (and 4 more...)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT03787238 |
GM-18 |
REAL |
March 1, 2019 |
August 1, 2020 |
August 1, 2020 |
December 25, 2018 |
December 25, 2018 |
|
- Danish Headache Center
Glostrup, Denmark - CTC, University Medical Center Hamburg-Eppendorf
Hamburg, Germany - Migräne- und Kopfschmerzklinik Königstein
Königstein im Taunus, Germany - (and 13 more...)
|
|
| 79 |
NCT00488514 |
Completed
Has Results |
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents |
|
- Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With the Indicated Drug-related Adverse Events
- Number of Participants With Any Adverse Event Categorized by Severity
- Number of Participants With Any Adverse Event Categorized Over Time
- (and 24 more...)
|
656 |
All |
12 Years to 17 Years (Child) |
NCT00488514 |
TXA107977 |
|
July 13, 2007 |
August 1, 2009 |
August 20, 2009 |
June 20, 2007 |
May 18, 2017 |
September 6, 2010 |
- GSK Investigational Site
Gilbert, Arizona, United States - GSK Investigational Site
Phoenix, Arizona, United States - GSK Investigational Site
Jonesboro, Arkansas, United States - (and 74 more...)
|
|
| 80 |
NCT03282227 |
Active, not recruiting |
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine |
|
- Drug: M207 Microneedle System
|
Interventional
|
Phase 3 |
- Zosano Pharma Corporation
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long-term safety as measured by incidence of adverse events
- Proportion of subjects with pain freedom
- Proportion of subjects with most bothersome symptom freedom
- (and 4 more...)
|
344 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03282227 |
CP-2017-001 |
ADAM |
November 7, 2017 |
March 2019 |
March 2019 |
September 13, 2017 |
January 31, 2019 |
|
- Achieve Clinical Research
Birmingham, Alabama, United States - Elite Clinical Studies
Phoenix, Arizona, United States - Downtown L.A. Research Center
Los Angeles, California, United States - (and 28 more...)
|
|
| 81 |
NCT02582996 |
Not yet recruiting |
Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks |
|
- Drug: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
- Drug: Acetaminophen
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain relief of Cefalium® compared to Tylenol®
- Pain decrease after use of investigational product, without a rescue medication
- Pain decrease after use of the investigational product, without a rescue medication
- (and 4 more...)
|
336 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02582996 |
ACH-CFL-03(01/14) |
|
April 2019 |
April 2020 |
June 2020 |
October 21, 2015 |
April 12, 2018 |
|
- Centro de Pesquisa Clínica - CPEC / Associação Obras Sociais Irmã Dulce
Salvador, Bahia, Brazil - Centro de Pesquisa Clínica Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande Do Sul, Brazil - Centro de Desenvolvimento em Estudos Clínicos Brasil - CDEC Brasil
São Paulo, Brazil - (and 3 more...)
|
|
| 82 |
NCT00742209 |
Completed
Has Results |
Prevention Study in Adult Patients Suffering From Migraine Headaches |
- Migraine Disorders
- Migraine
|
- Drug: GSK1838262
- Drug: Placebo
|
Interventional
|
Phase 2 |
- XenoPort, Inc.
- GlaxoSmithKline
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper
- Mean Change From Baseline in the Number of MHD in All Study Phases
- Adjusted Mean Change From Baseline in the Number of Migraine Attacks
- (and 12 more...)
|
526 |
All |
18 Years and older (Adult, Older Adult) |
NCT00742209 |
111381 |
|
August 2008 |
June 2010 |
June 2010 |
August 27, 2008 |
July 22, 2013 |
December 5, 2011 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Phoenix, Arizona, United States - GSK Investigational Site
Phoenix, Arizona, United States - (and 56 more...)
|
|
| 83 |
NCT00387881 |
Completed
Has Results |
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) |
|
- Drug: sumatriptan succinate / naproxen sodium
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.
- Freedom From Headache Pain at 0.5, 1, and 4 Hours After Treatment
- Sustained Headache Relief 2-24 Hours After Treatment
- (and 6 more...)
|
679 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00387881 |
TXA107563 |
|
September 2006 |
February 2008 |
February 2008 |
October 13, 2006 |
December 16, 2016 |
July 10, 2009 |
- GSK Investigational Site
Phoenix, Arizona, United States - GSK Investigational Site
Phoenix, Arizona, United States - GSK Investigational Site
Little Rock, Arkansas, United States - (and 67 more...)
|
|
| 84 |
NCT03217968 |
Completed
Has Results |
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device |
|
- Device: Cefaly® Abortive Program device
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain Freedom (PF) at 2 Hours
- Most Bothersome Migraine-associated Symptom (MBS) Freedom at 2 Hours
- Pain Relief (PR) at 2 Hours
- (and 3 more...)
|
59 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03217968 |
50803 |
|
August 10, 2017 |
January 10, 2018 |
January 10, 2018 |
July 14, 2017 |
August 7, 2018 |
June 7, 2018 |
- Rochester Clinical Research, Inc.
Rochester, New York, United States
|
|
| 85 |
NCT03432286 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the Number of Monthly Migraine Headache Days
- Proportion of Participants with Reduction from Baseline ≥50% in Monthly Migraine Headache Days
- Change from Baseline in the Number of Monthly Headache Days with Nausea and/or Vomiting
- (and 13 more...)
|
645 |
All |
6 Years to 17 Years (Child) |
NCT03432286 |
16352
I5Q-MC-CGAS
2017-004351-23 |
REBUILD |
March 14, 2018 |
May 31, 2021 |
June 25, 2022 |
February 14, 2018 |
January 15, 2019 |
|
- Medical Center for Clinical Research
San Diego, California, United States - Clinical Neuroscience Solutions Inc
Jacksonville, Florida, United States - Sensible Healthcare
Ocoee, Florida, United States - (and 13 more...)
|
|
| 86 |
NCT03185143 |
Completed |
Oral ALLOD-2 vs. Oral Sumatriptan and vs. Placebo in the Acute Treatment of Migraine With Associated Nausea (ANODYNE-2) |
- Migraine With and Without Aura
|
- Drug: ALLOD-2 Capsules
- Drug: Sumatriptan 100 mg Capsules
- Drug: Placebo capsules
|
Interventional
|
Phase 2
Phase 3 |
- Allodynic Therapeutics, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The proportion of patients having no headache pain at 2 hours.
- The proportion of patients having the absence of the most bothersome migraine-associated symptom at 2 hours.
- The proportion of patients having the absence of nausea, photophobia, phonophobia, and neck/shoulder pain at 2 hours.
- (and 4 more...)
|
36 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03185143 |
ANODYNE-2 |
|
June 27, 2017 |
May 7, 2018 |
May 7, 2018 |
June 14, 2017 |
May 11, 2018 |
|
- Annette C. Toledano, M.D.
North Miami, Florida, United States
|
|
| 87 |
NCT03061734 |
Completed |
Oral ALLOD-2 vs. Its Components & vs. Placebo in the Acute Treatment of Migraine (ANODYNE-1) |
- Migraine With or Without Aura
|
- Drug: ALLOD-2
- Drug: ALLOD-2H
- Drug: Component A (regular dose)
- (and 2 more...)
|
Interventional
|
Phase 2
Phase 3 |
- Allodynic Therapeutics, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The proportion of patients having no headache pain for ALLOD-2 vs. placebo at 2 hours.
- The proportion of patients having absence of most bothersome migraine-associated symptom-for ALLOD-2 vs. placebo at 2 hours.
- The proportion of patients having absence of nausea, photophobia, phonophobia, and neck/shoulder pain for ALLOD-2 and ALLOD-2H vs. placebo at 2 hours.
- (and 4 more...)
|
92 |
All |
18 Years and older (Adult, Older Adult) |
NCT03061734 |
ANODYNE-1 |
|
February 18, 2017 |
February 8, 2018 |
February 8, 2018 |
February 23, 2017 |
March 20, 2018 |
|
- Annette C. Toledano MD
North Miami, Florida, United States
|
|
| 88 |
NCT03341689 |
Recruiting |
Psilocybin for the Treatment of Migraine Headache |
|
- Drug: High Dose Psilocybin
- Drug: Low Dose Psilocybin
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Acute change in pain intensity
- Acute change in nausea/vomiting
- Acute change in photophobia
- (and 18 more...)
|
24 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03341689 |
1607018057.A |
|
November 1, 2017 |
November 1, 2019 |
March 1, 2020 |
November 14, 2017 |
February 4, 2019 |
|
- VA Connecticut Healthcare System, West Haven Campus
West Haven, Connecticut, United States
|
|
| 89 |
NCT03338920 |
Recruiting |
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents |
- Acute Migraine With or Without Aura
|
- Drug: sumatriptan nasal powder
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants who were headache pain free at 120 minutes after treatment
- Number of participants with headache relief at 120 minutes after treatment
- Number of participants who were headache pain free any time after treatment
- (and 9 more...)
|
420 |
All |
12 Years to 17 Years (Child) |
NCT03338920 |
17-AVP-825-301 |
|
November 2, 2017 |
November 2019 |
November 2019 |
November 9, 2017 |
February 8, 2019 |
|
- Phoenix Children's Hospital
Phoenix, Arizona, United States - eStudySite
Chula Vista, California, United States - Fullerton Neurology and Headache Center
Fullerton, California, United States - (and 37 more...)
|
|
| 90 |
NCT02438553 |
Completed |
Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain |
|
- Device: OSTNS Neurostimulator
- Device: Placebo OSTNS Neurostimulator
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Pain visual analogue scale (VAS)
- "Responder" rate at 20-60 minutes of treatment.
- "Responder" rate at 15 minutes of treatment
- (and 10 more...)
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02438553 |
NRLF-0086-14-MMC-CTIL |
|
May 2015 |
October 2015 |
October 2015 |
May 8, 2015 |
January 7, 2016 |
|
- Meir General Hospital
Kfar Saba, Israel
|
|
| 91 |
NCT01390324 |
Withdrawn |
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine |
|
- Drug: Fixed-dose combination of naratriptan+naproxen
- Drug: Naratriptan
- Drug: Naproxen
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Headache relief 2 hours after dosing, without use of rescue medication.
- Headache relief 4 hours after dosing, without use of rescue medication
- Sustained headache relief over 24 hours, without use of rescue medication
- (and 6 more...)
|
0 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01390324 |
ACH-NRP-03(05/11) |
Atenéia |
December 2011 |
March 2012 |
March 2012 |
July 11, 2011 |
October 19, 2016 |
|
|
|
| 92 |
NCT00904098 |
Completed |
Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine |
- Menstrual Migraine (MM) Headaches
|
- Drug: Frovatriptan
- Drug: Usual Care
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Headache pain severity
- Occurrence and severity of MM symptoms associated with migraine headache pain (nausea, vomiting, photophobia, and phonophobia)
- Occurrence and severity of functional impairment during menstrual migraine
- (and 4 more...)
|
192 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00904098 |
EN3266-401 |
|
September 2005 |
February 2006 |
February 2006 |
May 19, 2009 |
February 15, 2010 |
|
- Stratford, Connecticut, United States
- Clearwater, Florida, United States
- Jacksonville, Florida, United States
- (and 18 more...)
|
|
| 93 |
NCT01920945 |
Terminated |
OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study |
- New Daily Persistent Headache
|
|
Interventional
|
Phase 2 |
- St. Luke's-Roosevelt Hospital Center
- Allergan
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- change from baseline in frequency of headache days
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT01920945 |
ALLERGAN-13-002 |
|
September 2014 |
October 2016 |
October 2016 |
August 12, 2013 |
October 26, 2016 |
|
- Roosevelt Hospital Headache Institute
New York, New York, United States
|
|
| 94 |
NCT03488563 |
Recruiting |
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine |
|
- Biological: B244
- Biological: Vehicle
|
Interventional
|
Phase 2 |
- AOBiome LLC
- Veristat, Inc.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Mean change in monthly migraine days.
- Mean change in monthly migraine attacks.
- (and 5 more...)
|
303 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03488563 |
MGB244-001 |
|
March 30, 2018 |
February 20, 2019 |
February 20, 2019 |
April 5, 2018 |
December 11, 2018 |
|
- Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - Collaborative Neuroscience Network, LLC
Long Beach, California, United States - CI Trials
Riverside, California, United States - (and 19 more...)
|
|
| 95 |
NCT01799590 |
Completed
Has Results |
Continuous Treatment Study of Topiramate in Migraine Participants |
|
|
Interventional
|
Phase 2 |
- Janssen Pharmaceutical K.K.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events
- Change From Baseline in the Number of Monthly Migraine Attacks as Per 24-hour Rule in the Continuous Treatment Period
- Change From Baseline in the Average Number of Monthly Migraine Attack Days in Continuous Treatment Period
- (and 7 more...)
|
296 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT01799590 |
CR013684
JNS019-JPN-03 |
|
August 2007 |
November 2009 |
November 2009 |
February 27, 2013 |
May 31, 2013 |
May 6, 2013 |
- Chitose, Japan
- Hachioji, Japan
- Isehara, Japan
- (and 22 more...)
|
|
| 96 |
NCT01081795 |
Completed
Has Results |
A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine |
|
- Drug: Topiramate
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Pharmaceutical K.K.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6
- Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6
- Change From Baseline in Average Number of Monthly Headache Days at Month 1, 2, 3, 4, 5 and 6
- (and 7 more...)
|
387 |
All |
20 Years to 64 Years (Adult) |
NCT01081795 |
CR013681
JNS019-JPN-02 |
|
April 2007 |
January 2009 |
January 2009 |
March 5, 2010 |
July 2, 2013 |
May 6, 2013 |
- Bunkyo, Japan
- Chitose, Japan
- Hachioji, Japan
- (and 27 more...)
|
|
| 97 |
NCT03526874 |
Not yet recruiting |
Occipital Blocks for Acute Migraine |
- Chronic Migraine, Headache
- Episodic Migraine
|
- Drug: Lidocaine 4% Topical Application Cream [LMX 4]
- Drug: Lidocaine Hydrochloride 2 mg/mL Injectable Solution
- Drug: Normal Saline
|
Interventional
|
Phase 3 |
- Children's Hospital of Philadelphia
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change in Pain Intensity Scores
- Change from Baseline Disability
- Percentage of Subjects with Pain Freedom
- (and 3 more...)
|
58 |
All |
7 Years to 17 Years (Child) |
NCT03526874 |
18-014939 |
|
April 2019 |
November 2021 |
December 2021 |
May 16, 2018 |
February 6, 2019 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 98 |
NCT00804973 |
Terminated |
Study in Subjects With Acute Migraines Headaches. |
|
- Drug: LY2590443
- Drug: Placebo injection
- Drug: Sumatriptan
- Drug: Placebo capsule
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Headache pain free response.
- Pain free response
- Pain relief response.
- (and 7 more...)
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00804973 |
12258
I2W-MC-DMAB |
|
November 2008 |
May 2009 |
May 2009 |
December 9, 2008 |
April 20, 2010 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beverly Hills, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chula Vista, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fresno, California, United States - (and 16 more...)
|
|
| 99 |
NCT03167060 |
Completed |
BrainCool-Migraine Intranasal Cooling Trial |
|
- Device: Active RhinoChill
- Device: Control Rhinochill
|
Interventional
|
Not Applicable |
- Cumbria Partnership NHS Foundation Trust
- BrainCool AB
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Participant is pain free at two hours following trial device treatment The patients' first treatment will be used for analysis of the superiority of the rate of patients pain free at two hours following treatment for those receiving the standard R
- Percentage of patients pain free immediately after treatment (10 minutes), at 1 hour, and 24 hours following treatment
- Headache response
- (and 3 more...)
|
90 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03167060 |
CP1628 |
|
May 8, 2017 |
January 31, 2019 |
February 6, 2019 |
May 25, 2017 |
February 11, 2019 |
|
- Neurosciences department, Penrith Hospital, Cumbria Partnership NHS Foundation Trust
Penrith, Cumbria, United Kingdom - South tees Hospital
Middlesbrough, United Kingdom - The Newcastle upon Tyne Hospitals
Newcastle upon Tyne, United Kingdom - City Hospital, Sunderland, UK
Sunderland, United Kingdom
|
|
| 100 |
NCT01228552 |
Unknown † |
The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine |
- Migraine Disorders
- Migraine Headache
- Migraine
- Acute Migraine
|
- Drug: Topical, intra-oral ketoprofen gel
- Other: Placebo gel
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain relief (defined as at least 2 graded reduction in a 5-grade scale) at 120 minutes post-treatment
- Pain free status at 30, 60, 120, and 240 minutes post-treatment based on headache severities reported in patient's journals
- Pain relief at 30, 60, and 240 minutes post-treatment based on headache severities reported in patient's journals
- (and 5 more...)
|
100 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01228552 |
79,629 |
|
December 2011 |
January 2012 |
January 2012 |
October 26, 2010 |
June 8, 2011 |
|
- New York Medical College
Valhalla, New York, United States
|
|
Create an RSS feed from your search for:
Download the search results for: